Shilpa Medicare has received EU GMP status for its Finished Dosage Formulation Facility (Sterile and Non-sterile) located at Pharmaceutical Formulations SEZ, TSIIC, Jadcherla, Telangana State, India from Austrian Authority (AGES) for the inspection held during January 13, 2020 to January 17, 2020.
The company’s affiliates have registered their products (Oral solids & Injections) with European authorities for commercial distribution. The renewed EU GMP facilitates continued supply of products to European Union.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
